Attenuating Cancer Treatment-related Toxicity in Oncology Patients With a Tailored Physical Exerc… (NCT03787966) | Clinical Trial Compass
CompletedNot Applicable
Attenuating Cancer Treatment-related Toxicity in Oncology Patients With a Tailored Physical Exercise Program
Spain100 participantsStarted 2019-09-01
Plain-language summary
The aim of this study is to determine if therapeutic exercise before anticancer treatment will mitigate the onset or extent of cardiotoxicity comparing to therapeutic exercise performed during anticancer treatment.
Who can participate
Age range18 Years – 70 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* 18 years or older
* Breast cancer diagnosis I-III stage
* On the waiting list to anticancer medical treatment (at least surgery, chemotherapy and radiotherapy.
* If they meet other criteria which predisposes to higher toxicity.
* Have signed informed consent.
* Have medical clearance for participation.
Exclusion Criteria:
* Patient underwent previous cancer treatments.
* Patients were previously diagnosed with cancer.
* Pregnant patients.
* Patients performing other type of therapeutic exercise at diagnosis time with an intake \>or = to 150 moderate-intensity or 75 min of vigorous-intensity a day.
* Therapeutic exercise practice not recommended because psychiatric or cognitive disorders or cute or chronic condition that prevents exercise (advanced lung disease, oxygen requirement, stenosis \>70%, metastasis etc.).
What they're measuring
1
Left ventricular ejection fraction
Timeframe: Participants will be followed over 12 months